RVMD

Revolution Medicines, Inc. (RVMD) | Rumor.io

Revolution Medicines

RVMD

Attention (50-day avg)0.01%

Attention rank (50-day avg)#446

Bullish sentiment (50-day avg)86%

Price to earnings ratio-34

Market capitalization43.2B

Earnings per share-8.87

Dividend yield (TTM)—

Revenue (annual)0

Net income (annual)-1.1B

Social

What share of all stock conversation is about RVMD?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0.01% -0.01	0.01% +0.01	0.01% -0.01	0.01% +0.01

Sep 26

Revolution Medicines' team is fully on the ground at AACR in San Diego, where SELLAS dropped landmark data showing SLS009 produces a >6-fold increase in apoptosis and drives cell death past 67% in daraxonrasib-resistant PDAC models.
SLS009 restores sensitivity and breaks the resistance mechanism that inevitably hits RAS inhibitors, making it a prime pre-acquired asset for Big Pharma.
The PIVOTAL Trial data for SLS009 is expected to be announced next quarter, and the company could sell Tambiciclib for 2x the current short-rigged market capitalization or 10x when the data is announced.

Generated by AI

Sentiment

Of the messages about RVMD that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	100% 0	98.71% +25.57	83.69% -3.52	85.14% -7.68
Bearish	0% 0	1.29% -25.57	16.31% +3.52	14.86% +7.68

Bullish· Aug 27

Revolution Medicines, Inc. ($RVMD) has secured FDA approval for Rasonque, a treatment for second-line metastatic pancreatic cancer, which has the potential to generate peak sales above $20B.
The company's FDA approval for Rasonque has been met with a bullish market reaction, with analysts raising their price targets and the stock price reaching new highs.
The approval of Rasonque has expanded the addressable market for Revolution Medicines, with the company now able to treat patients without the RAS+ biomarker, and analysts believe that the upside has not been fully priced in based on the approval.

Bearish· Jun 2

$RVMD's recent breakthrough in cancer treatment, which more than doubled survival times of pancreatic cancer, may not be enough to sustain its stock price, as seen in its lack of movement despite the announcement.
The company's stock price may be vulnerable to profit-taking after the initial hype from the ASCO meeting, potentially leading to a decline back to the $140 range.
$RVMD's stock price may be experiencing a sell-off due to the recent success of another company, ABVX, which overshadowed $RVMD's own news and caused a decline in its stock price.

Generated by AI

Topics

Of the messages about RVMD that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	64%	84.07%	75.45%	47.77%
Analysts	28%	14.16%	13.32%	23.47%
Technical Analysis	8%	1.77%	2.4%	1.58%
Macro	0%	0%	8.83%	26.25%
Earnings	0%	0%	0%	0.3%
Controversies	0%	0%	0%	0.62%

Aug 27

Revolution Medicines' ($RVMD) RASONQUE has received FDA approval for the treatment of adult patients with metastatic pancreatic cancer, nearly doubling median survival in previously treated patients.
Analysts expect peak sales for Revolution Medicines' ($RVMD) RASONQUE to exceed $20 billion, with some predicting sales of $2.3 billion by 2028.
The FDA approval of RASONQUE has led to a significant increase in the stock price of Revolution Medicines ($RVMD), with analysts predicting further growth and a potential list price of $400 per share by 2030.

Generated by AI

Community

Of the messages about RVMD, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	87.5%	79.53%	79.38%	38.75%
Newcomers	12.5%	20.47%	20.62%	61.25%

Regulars· Sep 3

The newly published Phase 1/2 data for Revolution Medicines' RASONQUE (daraxonrasib) in metastatic non-small cell lung cancer shows a 42% response rate in a subgroup of patients.
The data from the subgroup are considered the most relevant to Revolution Medicines' ongoing Phase 3 test in RAS mutant NSCLC, and could potentially hold up in the trial.
Merck's potential acquisition of Revolution Medicines for $28-32 billion is being speculated, as the company's M&A chief expects "a lot more deal flow" with the Keytruda patent cliff nearing.

Newcomers· Sep 11

New users are discussing a large trade on $RVMD, with a $2.73M buy of $200 calls expiring in 2026, indicating a bullish sentiment.
The IV (implied volatility) on the trade is 47%, which is relatively high and may indicate a higher level of uncertainty or risk.
There is currently zero bearish flow on the asset, which could suggest that the trade is taking a significant position in the market.

Generated by AI

News

Brookline initiates Revolution Medicines stock with buy rating

2d agoInvesting.com

Is Buying Royalty Pharma Stock a Safer Way to Bet on Revolution Medicines? | The Motley Fool

Revolution Medicines' stock is up 330% in a year on drug development progress; you may want to spread your bets with Royalty Pharma instead.

5d agoThe Motley Fool

Revolution Medicines director Elizabeth Anderson sells $1.96m in stock

5d agoInvesting.com

Is Revolution Medicines (RVMD) Cheap After Its FDA Breakthrough Therapy Win?

7d agoYahoo Finance

Revolution Medicines (RVMD) Deepens RAS(ON) Bet With Breakthrough PDAC Combo – But Is Risk Repricing?

Earlier in September 2026, Revolution Medicines announced that the FDA granted Breakthrough Therapy Designation to RASONQUE (daraxonrasib) plus chemotherapy for treatment‑naïve metastatic pancreatic adenocarcinoma, adding to its existing U.S. approval in later‑line PDAC. The company was also added to the FTSE All‑World Index (USD), potentially broadening its shareholder base as it advances a late‑stage RAS(ON) pipeline in a cancer with very limited treatment options. With Breakthrough...

7d agoYahoo Finance

AIM ImmunoTech Highlights Ampligen’s Potential Role in the Evolving Pancreatic Cancer Treatment Landscape Following FDA Approval of Revolution Medicines’ Daraxonrasib

Company CEO outlines the differentiated mechanism and clinical potential of Ampligen in pancreatic cancerSurvival data highlighted in accompanying...

7d agomarkets.businessinsider.com

Also Discussed

Investors talking about RVMD also mention

#	Name	Attention
1	Abivax SAABVX	0.01%-0.01
2	Maze Therapeutics, Inc.MAZE	0%0
3	Erasca Inc.ERAS	0%0
4	Immuneering Corp. Class A Common StockIMRX	0%0
5	Mineralys Therapeutics, Inc.MLYS	0%+0
6	Tango Therapeutics Inc.TNGX	0%new
7	IDEAYA Biosciences Inc.IDYA	0%0
8	Edgewise Therapeutics Inc.EWTX	0%new
9	Denali Therapeutics Inc.DNLI	0%new
10	Replimune Group, Inc.REPL	0%0

Revolution Medicines, Inc.

Healthcare
Biotechnology

Revolution Medicines, Inc. is a clinical-stage precision oncology company focused on developing targeted therapies for RAS-addicted cancers. The company applies proprietary drug discovery capabilities to create small-molecule medicines designed to act on challenging RAS pathway targets, a central driver in many aggressive tumors. Its current pipeline includes RAS(ON) inhibitors and companion inhibitors being studied as monotherapies and in combination regimens to address cancers with specific RAS mutations and related pathway dependencies. Revolution Medicines concentrates on areas of high unmet medical need, including pancreatic, lung, and colorectal cancers, and its work is aimed at improving how these diseases are treated in modern oncology practice. Headquartered in Redwood City, California, and founded in 2014, Revolution Medicines occupies a specialized position in the biotechnology sector through its focus on advanced precision medicine approaches.

Website

Location

700 Saginaw Drive

Redwood City, CA, 94063

United States

Social

What share of all stock conversation is about RVMD?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0.01% -0.01	0.01% +0.01	0.01% -0.01	0.01% +0.01

Sep 26

Revolution Medicines' team is fully on the ground at AACR in San Diego, where SELLAS dropped landmark data showing SLS009 produces a >6-fold increase in apoptosis and drives cell death past 67% in daraxonrasib-resistant PDAC models.
SLS009 restores sensitivity and breaks the resistance mechanism that inevitably hits RAS inhibitors, making it a prime pre-acquired asset for Big Pharma.
The PIVOTAL Trial data for SLS009 is expected to be announced next quarter, and the company could sell Tambiciclib for 2x the current short-rigged market capitalization or 10x when the data is announced.

Generated by AI

Sentiment

Of the messages about RVMD that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	100% 0	98.71% +25.57	83.69% -3.52	85.14% -7.68
Bearish	0% 0	1.29% -25.57	16.31% +3.52	14.86% +7.68

Bullish· Aug 27

Revolution Medicines, Inc. ($RVMD) has secured FDA approval for Rasonque, a treatment for second-line metastatic pancreatic cancer, which has the potential to generate peak sales above $20B.
The company's FDA approval for Rasonque has been met with a bullish market reaction, with analysts raising their price targets and the stock price reaching new highs.
The approval of Rasonque has expanded the addressable market for Revolution Medicines, with the company now able to treat patients without the RAS+ biomarker, and analysts believe that the upside has not been fully priced in based on the approval.

Bearish· Jun 2

$RVMD's recent breakthrough in cancer treatment, which more than doubled survival times of pancreatic cancer, may not be enough to sustain its stock price, as seen in its lack of movement despite the announcement.
The company's stock price may be vulnerable to profit-taking after the initial hype from the ASCO meeting, potentially leading to a decline back to the $140 range.
$RVMD's stock price may be experiencing a sell-off due to the recent success of another company, ABVX, which overshadowed $RVMD's own news and caused a decline in its stock price.

Generated by AI

Topics

Of the messages about RVMD that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	64%	84.07%	75.45%	47.77%
Analysts	28%	14.16%	13.32%	23.47%
Technical Analysis	8%	1.77%	2.4%	1.58%
Macro	0%	0%	8.83%	26.25%
Earnings	0%	0%	0%	0.3%
Controversies	0%	0%	0%	0.62%

Aug 27

Revolution Medicines' ($RVMD) RASONQUE has received FDA approval for the treatment of adult patients with metastatic pancreatic cancer, nearly doubling median survival in previously treated patients.
Analysts expect peak sales for Revolution Medicines' ($RVMD) RASONQUE to exceed $20 billion, with some predicting sales of $2.3 billion by 2028.
The FDA approval of RASONQUE has led to a significant increase in the stock price of Revolution Medicines ($RVMD), with analysts predicting further growth and a potential list price of $400 per share by 2030.

Generated by AI

Community

Of the messages about RVMD, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	87.5%	79.53%	79.38%	38.75%
Newcomers	12.5%	20.47%	20.62%	61.25%

Regulars· Sep 3

The newly published Phase 1/2 data for Revolution Medicines' RASONQUE (daraxonrasib) in metastatic non-small cell lung cancer shows a 42% response rate in a subgroup of patients.
The data from the subgroup are considered the most relevant to Revolution Medicines' ongoing Phase 3 test in RAS mutant NSCLC, and could potentially hold up in the trial.
Merck's potential acquisition of Revolution Medicines for $28-32 billion is being speculated, as the company's M&A chief expects "a lot more deal flow" with the Keytruda patent cliff nearing.

Newcomers· Sep 11

New users are discussing a large trade on $RVMD, with a $2.73M buy of $200 calls expiring in 2026, indicating a bullish sentiment.
The IV (implied volatility) on the trade is 47%, which is relatively high and may indicate a higher level of uncertainty or risk.
There is currently zero bearish flow on the asset, which could suggest that the trade is taking a significant position in the market.

Generated by AI

Revolution Medicines

Social

Sep 26

Bullish· Aug 27

Bearish· Jun 2

Aug 27

Regulars· Sep 3

Newcomers· Sep 11

Brookline initiates Revolution Medicines stock with buy rating

Is Buying Royalty Pharma Stock a Safer Way to Bet on Revolution Medicines? | The Motley Fool

Revolution Medicines director Elizabeth Anderson sells $1.96m in stock

Is Revolution Medicines (RVMD) Cheap After Its FDA Breakthrough Therapy Win?

Revolution Medicines (RVMD) Deepens RAS(ON) Bet With Breakthrough PDAC Combo – But Is Risk Repricing?

AIM ImmunoTech Highlights Ampligen’s Potential Role in the Evolving Pancreatic Cancer Treatment Landscape Following FDA Approval of Revolution Medicines’ Daraxonrasib

Also Discussed

Revolution Medicines, Inc.

Company Information

Location

Brookline initiates Revolution Medicines stock with buy rating

Is Buying Royalty Pharma Stock a Safer Way to Bet on Revolution Medicines? | The Motley Fool

Revolution Medicines director Elizabeth Anderson sells $1.96m in stock

Is Revolution Medicines (RVMD) Cheap After Its FDA Breakthrough Therapy Win?

Revolution Medicines (RVMD) Deepens RAS(ON) Bet With Breakthrough PDAC Combo – But Is Risk Repricing?

AIM ImmunoTech Highlights Ampligen’s Potential Role in the Evolving Pancreatic Cancer Treatment Landscape Following FDA Approval of Revolution Medicines’ Daraxonrasib

Also Discussed

Social

Sep 26

Bullish· Aug 27

Bearish· Jun 2

Aug 27

Regulars· Sep 3

Newcomers· Sep 11